Clinical Trial Update: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of GTB-3550 Tri-Specific Killer Engager (TriKE) for high-risk hematologic malignancies has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndromes
• Mast Cell Leukemia
• Systemic Mastocytosis

Drugs mentioned

• GTB-3550 Tri-Specific Killer Engager (TriKE) (GTB-3550 Tri-Specific Killer Engager (TriKE))

Snippet

Sponsor: GT Biopharma, Inc. | Conditions: High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-11-10